Results 151 to 160 of about 30,003 (287)

Biosimilars are not (bio)generics [PDF]

, 2010
K. L. Lynch, Ross A. McKinnon, Chun‐Hao Lu   +2 more
openalex   +1 more source

Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis

Arthritis Care &Research, Volume 77, Issue 7, Page 813-826, July 2025.
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We conducted a systematic literature search for RCTs assessing the efficacy of advanced therapies in patients with axSpA ...
Angel Gao, Jordi Pardo Pardo, Steven Dang, Lianne S. Gensler, Philip Mease, Lihi Eder   +5 more
wiley   +1 more source

PSY15 Striving for Affordable Treatments Within the Greek Environment: Do Epoetin Biosimilars Help? [PDF]

, 2011
Chara Kani, P. Litsa, E. Alexopoulou, M. Hatzikou, Sossana Delibasi, Mary Geitona   +5 more
openalex   +1 more source

Prescribing biosimilars [PDF]

BMJ, 2018
Aronson, J, Goldacre, B, Ferner, R
openaire   +2 more sources

Appraising the visibility, relevance and impacts of clinical pharmacology

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 1884-1898, July 2025.
Aims Clinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
Serge Cremers, Samuel L. M. Arnold, Nilima A. Kshirsagar, Catriona Waitt, Olayinka O. Ogunleye, Lars L. Gustafsson   +5 more
wiley   +1 more source

Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review

ClinicoEconomics and Outcomes Research
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Fox GE, Bernauer M, Stephens JM, Jackson B, Roth JA, Shelbaya A   +5 more
doaj  

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

Biosimilar, biobetter and next generation therapeutic antibodies [PDF]

, 2011
Alain Beck
openalex   +1 more source

Temporal Galactose‐Manganese Feeding in Fed‐Batch and Perfusion Bioreactors Modulates UDP‐Galactose Pools for Enhanced mAb Glycosylation Homogeneity

Biotechnology and Bioengineering, Volume 122, Issue 7, Page 1710-1723, July 2025.
This study investigates the temporal effects of galactose and manganese on the N‐glycosylation of Trastuzumab (mAb) antibody during fed‐batch and perfusion bioprocessing modes to reveal the influence of feeding schedules on mAb N‐glycosylation patterns. These findings will aid in building process control schemes for mAb bioprocessing.
Aron Gyorgypal, Erica Fratz‐Berilla, Casey Kohnhorst, David N. Powers, Shishir P. S. Chundawat   +4 more
wiley   +1 more source

Worldwide experience with biosimilar development [PDF]

, 2011
Mark McCamish, Gillian R. Woollett
openalex   +1 more source